1.Establishment of a fuzzy mathematical model for syndrome differentiation of gastric cancer.
Long LIU ; Ling XU ; Dazhi SUN ; Pinkang WEI
Journal of Integrative Medicine 2008;6(11):1117-21
To probe into a method for establishing the fuzzy mathematical model for syndrome differentiation of gastric cancer.
2.Effect of irbesartan on nephrin expression in the podocyte of early diabetic nephropathy rats
Haibo LONG ; Juan ZHONG ; Lianbo WEI ; Weidong ZHOU ; Zhaozhong XU
Chinese Journal of Pathophysiology 1989;0(06):-
AIM: To investigate the expression of the nephrin in podocyte of the diabetic nephropathy(DN) rats and the mechanism of irbesartan-induced renal protection.METHODS: The DN model was established by a single injection of streptozotocin(STZ),and DN rats were randomly divided into 2 groups: model group and irbesartan treatment group.In addition,the normal rats served as a normal control group. All the rats were received daily gavage respectively for 8 weeks. The urinary protein quality in 24 hours,body weight(BW),kidney weight (KW),KW/BW,glucemia,urea nitrogen,creatinine,total cholesterol, triacylglycerol were detected with correlative methods and the pathological changes of kidney were also detected with optic microscope and transmission electron microscope.The expression of nephrin in podocyte were detected by immunohistochemistry. RESULTS: In DN rats, irbesartan reduced the urinary protein quality in 24 hours (P
3.Report of state monitory network in the Kaschin-Beck Disease area , Gansu province in 2000
Ji-min, XU ; Wen-long, WANG ; Zhou-bang, WEI
Chinese Journal of Endemiology 2001;20(2):132-133
Objective According to Kaschin-Beck Disea se monitory standardization that had been adjusted by our country,we monitored the state of Kaschin-Beck Disease in Gansu province.Methods So as to understand change of illness,we took methods of epidemiological investigation,clinical examination and X-ray diagnosis.Results It is not detected in the clinical that patient suffered from more than I of KBD among 7~12 years old in Qingyang monitory netw ork.X-ray detectable rate is 3%,but 12 cases patients were showed in Zhangjiach uan.X-ray detectable rate is 22.22%.Conclusions Illness was showed steady state and was con trolled in Qingyang region,but illness recurred clearly in Zhangjiachuan region.
4.Not Available.
Long long CHENG ; Rong hui XU ; Wei YOU ; Hai xia WANG
Journal of Forensic Medicine 2021;37(5):749-751
5.Expression and Purification of a Novel Influenza Virus Subunit Vaccine
Yi-Ju WEI ; Hai-Ting LONG ; Xu YANG ; Jian-Fang LI ; Yan-Wei BI ; Jian-Feng LI ; Wei-Ming XU ;
China Biotechnology 2006;0(05):-
The influenza A virus matrix protein2 gene(M2)which deleted transmembrane region was amplified by overlap extending PCR,and the multiepitope gene of hemagglutinin(HA)was PCR amplified with seven continuous synthesized segments by designing primer.The two gene segments were separately cloned into pMD18T vector to sequence analysis and prokarytic expression vector pET28a+ to construct the recombinant plasmid pET28a+M2dHA.The recombinant plasmid was transformed into E.coli BL21(DE3),and the high expression strain was obtained by screening monoclones.The recombinant protein existed as inclusion bodies,which accounted about 45% of the total cellular protein.The inclusion bodies were washed with 1% Triton X100 solution twice,and dissolved in 8 mol/L urea solution.The solution protein was purified by Ni+2 affinity chromatography,and refolded by dilution renaturation,then purified by Q Sepharose FF cation exchange column.The purity of the protein was over 90% by HPLC analysis.The result of Western blot showed it has good antigenicity and specificity.These results strongly supported for the further study of the broadspectrum influenza virus subunit vaccine.
6.Master documentation and records in the clinical data management.
Hua-long SUN ; Gang XU ; Wei LI ; Zhao-hui WEI ; Li DING
Acta Pharmaceutica Sinica 2015;50(11):1365-1366
This list of clincal data management documentation is to ensure standardized and adequate archival of trial documents and records in clinical data management, which is applicable to all of phase I-IV clinical trials.
Clinical Trials as Topic
;
Data Collection
;
standards
;
Documentation
;
standards
7.Research progression on safety verification of diving decompression procedures
ZHOU Ying jie ZHU Bao liang ZHANG Kun QING Long WANG Ye wei XU Wei gang
China Occupational Medicine 2022;49(06):712-
A diving decompression procedure is a specific rule that divers should follow when they ascend and get out of water. It
comes from the decompression theory and algorithm and is designed for the prevention of decompression sickness. With the
, ,
development of diving technology and diving medicine the decompression procedures are constantly innovated and the new
,
decompression procedure can be used in diving practice after safety verification. In principle the safety verification of
,
decompression procedures should be conducted on animal experiments before human experiments and the risks of
,
decompression sickness and oxygen toxicity should be systematically assessed. However the assessment methods used in
, , ,
different studies differ greatly thus it is urgent to establish a standard and universal verification system. Traditionally the risk
, ,
assessment of decompression sickness and oxygen toxicity is mainly carried out by observing the incidence detecting bubbles
,
theoretical calculation and lung functional test. Furthermore biochemical indicators are increasingly becoming important
, ,
supplements. Due to the special underwater environment the diving operation is prone to accidents. Therefore in addition to
,
verifying the safety of the new decompression procedure exploring its safety decompression limit is of great significance for the
formulation of emergency decompression procedures in emergency situations. The specific approach is to shorten the
decompression time and assess the safety until the critical time for detecting bubbles without the occurrence of decompression
, ,
sickness is found. Future studies should continue to optimize safety assessment methods explore sensitive biochemical markers
,
clarify species associations and improve verification efficiency and reliability of results.
8.Dose-effect relationship of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol in pediatric patients undergoing gastroenteroscopy
Huanhuan ZHANG ; Yonghong TAN ; Xingrong SONG ; Yingyi XU ; Wei WEI ; Xiaofen LONG
Chinese Journal of Anesthesiology 2021;41(2):195-197
Objective:To determine the dose-effect relationship of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol in pediatric patients undergoing gastroenteroscopy.Methods:Pediatric patients, aged 3-8 yr, of American Society of Anesthesiologists physical statusⅠ or Ⅱ, scheduled for elective gastroenteroscopy, were enrolled in the study.The doses of nalbuphine were determined by up-down sequential allocation, nalbuphine 0.2 mg/kg was injected intravenously in the first child, and 5 min later medium plus long chain triglyceride propofol 2.5 mg/kg was given intravenously.Ambesh 4-point method was used to evaluate the injection pain of propofol.When the prevention of injection pain was ineffective, the dose of nalbuphine was increased in the next patient, otherwise the dose was reduced, and the difference between the two successive doses was 0.01 mg/kg.This process was repeated until the 7th turning point occurred.The ED 50 and ED 95 of nalbuphine and 95% confidence interval (CI) preventing injection pain of propofol were calculated by Probit regression. Results:The ED 50 and ED 95 (95% CI) of nalbuphine preventing medium plus long chain triglyceride propofol injection pain were 1.57 (1.50-1.62) and 1.71 (1.64-2.05) mg/kg, respectively. Conclusion:The ED 50 and ED 95 of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol are 1.57 and 1.71 mg/kg, respectively, in pediatric patients undergoing gastroenteroscopy.
9.Preparation and Pegylation of TNF-? Derivative
Yan-Wei BI ; Na LUO ; Hai-Ting LONG ; Zeng-Fu YANG ; Xu YANG ; Jian-Feng LI ; Wei-Ming XU ;
China Biotechnology 2006;0(12):-
The gene of mutated TNF-?D4 gene was amplified by overlap PCR and cloned into the prokaryotic expressive vector pBV220.TNF-?D4 contains two changes:substitutions of Pro8Arg,Ser9Lys,Asp10Arg,Ile157Phe,Leu29Ser,Arg31Val and a deletion of the N terminal four amino acids.The recombinant vector pBV220-TNF-?D4 was transformated into E.coli strain DH5?,and the high expression strain was obtained by screening monoclones.The level of expression was about 45% of total cell protein.After purification,the purity of fusion protein was above 90% by HPLC and relative ability was 8 ?107.TNF-?D4 was modificated by mPEG-ButyrALD。After purification,the purity of mPEG-TNF-?D4 was above 85% and relative ability was 8.6?107.The in vivo systemic toxicity of mPEG-TNF-?D4,which is indicated by LD50,is lower than that of rhTNF-?.These results strongly supported for the further study and exploitation of TNF-antitumor drug.
10.Surgical treatment for posterior Pilon fracture through posterolateral approach.
Shao-hua JIA ; Cheng-long HUANG ; Hong-wei XU ; Sui-liang GONG
China Journal of Orthopaedics and Traumatology 2016;29(6):557-560
OBJECTIVETo explore clinical results of open reduction and internal fixation (ORIF) for posterior Pilon fracture through posterolateral approach.
METHODSSeventeen patients with posterior Pilon fracture were treated through posterolateral approach from February 2010 to April 2013. Among them,including 11 males and 6 females aged from 29 to 59 with an average of 43.4 years old. All fractures were associated with more than 20% of articular surface of distal tibial. The causes of injury included falling down (11 cases), traffic accident (4 cases) and sports injury(6 cases). Fracture classification was based on posterior pilon fracture by YU Guang-rong, including type I (6 cases), type II (2 cases) and type III (6 cases). Fracture healing time, fracture reduction and postoperative complications were observed, AOFAS score were applied to evaluate clinical efficacy.
RESULTSAll patients were followed up from 13 to 24 months with an average of 20.5 months. All incisions were healed at stage I, and fractures obtained healing,the time of fracture healing ranged from 12 to 21 weeks with an average of 15.2 weeks. No incision infection, neurovascular injury, bone ununion and fracture deformity were found after operation. Postoperative AOFAS score was 92.0 ± 10.2, and 14 cases got excellent results, 2 good and 1 moderate.
CONCLUSIONPosterior pilon fracture through posterolateral approach could obtain effective reduction, stable fixation. It is a safe, simple and effective operation for treating posterior Pilon fracture, and it is worth popularizing.
Adult ; Ankle Fractures ; surgery ; Ankle Joint ; surgery ; Female ; Fracture Fixation, Internal ; Humans ; Male ; Middle Aged ; Tibial Fractures ; surgery